

Application No. 10/042,711
Paper Dated: January 22, 2010
In Reply to USPTO Correspondence of July 22, 2010
Attorney Docket No. ENZ-57(CIP)(C) (4395/025)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1-38. (CANCELLED)

Claim 39. (CURRENTLY AMENDED) A method for developing a therapeutic procedure in a model animal system comprising the steps of:

- a) infecting *Tupaia belangeri* with a human viral pathogen, wherein said pathogen is HCV, HIV 1 or HIV 2;
- b) carrying out a potential therapeutic procedure in said infected *Tupaia belangeri*; and
- c) evaluating the effect of said therapeutic procedure on disease manifestations caused by said human viral pathogen in said infected animal.

Claims 40-42. (CANCELLED)

Claim 43. (PREVIOUSLY PRESENTED) The method of claim 39 wherein said therapeutic procedure comprises oral tolerization.

Claims 44-48. (CANCELLED)

Claim 49. (CURRENTLY AMENDED) A method for developing a therapeutic procedure which alleviates clinical manifestations of a disease caused by a human viral pathogen, wherein said pathogen is HCV, HIV 1 or HIV 2, comprising the steps of:

- a) infecting *Tupaia belangeri* with a human viral pathogen, wherein said pathogen is HCV, HIV 1 or HIV 2;
- b) carrying out a potential therapeutic procedure in said infected *Tupaia belangeri*;

Application No. 10/042,711
Paper Dated: January 22, 2010
In Reply to USPTO Correspondence of July 22, 2010
Attorney Docket No. ENZ-57(CIP)(C) (4395/025)

and

- c) evaluating the effect of said therapeutic procedure on clinical manifestations caused by said human viral pathogen.

Claim 50. (PREVIOUSLY PRESENTED) The method of claim 49 wherein said therapeutic procedure comprises oral tolerization.

Claim 51. (PREVIOUSLY PRESENTED) The method of claim 49 wherein said clinical manifestations are secondary disease manifestations of said infection and wherein said disease manifestations are inflammation, fibrosis, induced auto-immunity, apoptosis or a combination thereof.

Claims 52-57. (CANCELLED)

Claim 58. (CURRENTLY AMENDED) A method for developing a therapeutic procedure in a model animal system comprising the steps of:

- a) infecting *Tupaia belangeri* with a human viral pathogen, wherein said pathogen is HCV, HIV 1 or HIV 2;
- b) carrying out a potential therapeutic procedure in said infected *Tupaia belangeri*; and
- c) evaluating the effect of said therapeutic procedure on secondary disease manifestations caused by said human viral pathogen in said infected *Tupaia belangeri* wherein said disease manifestations are inflammation, fibrosis, induced auto-immunity, apoptosis or a combination thereof.

Claim 59. (CANCELLED)

Claims 60-61. (CANCELLED)

Application No. 10/042,711
Paper Dated: January 22, 2010
In Reply to USPTO Correspondence of July 22, 2010
Attorney Docket No. ENZ-57(CIP)(C) (4395/025)

Claim 62. (CURRENTLY AMENDED) The method of claim 58 wherein said human viral pathogen is HBV or ~~HCV~~.

Claim 63. (PREVIOUSLY PRESENTED) The method of claim 58 wherein said therapeutic procedure comprises oral tolerization.

Claims 64-68. (CANCELLED)

Claim 69. (CURRENTLY AMENDED) A method for developing a therapeutic procedure which alleviates secondary clinical manifestations of a disease caused by a human viral pathogen comprising the steps of:

- a) infecting *Tupaia belangeri* with a human viral pathogen, wherein said pathogen is HCV, HIV 1 or HIV 2;
- b) carrying out a potential therapeutic procedure in said infected *Tupaia belangeri*; and
- c) evaluating the effect of said therapeutic procedure on clinical manifestations caused by said human viral pathogen in said infected *Tupaia belangeri* wherein said clinical manifestations are inflammation, fibrosis, induced auto-immunity, apoptosis or combination thereof.

Claims 70-72. (CANCELLED)

Claim 73. (CURRENTLY AMENDED) The method of claim 69 wherein said human viral pathogen is HBV or ~~HCV~~.

Claim 74. (PREVIOUSLY PRESENTED) The method of claim 69 wherein said therapeutic procedure comprises oral tolerization.